Optic neuritis with visual field defect--possible Ibuprofen-related toxicity.
OBJECTIVE
To report a case of optic neuritis with visual field defect associated with ibuprofen.


METHODS
A 41-year-old white man developed blurred vision in his right eye and pain with eye and head movements that lasted 2 days after use of ibuprofen 400 mg 3 times daily during the preceding 3 weeks. Medical and family histories were negative for significant related disease. Ophthalmologic examination revealed a marked decrease in visual acuity to 20/200 in the right eye with quadrant visual field loss and absent responses in visual evoked potential (VEP). After discontinuation of the drug and treatment with high-dose intravenous methylprednisolone and subcutaneous low-molecular-weight heparin, the patient's vision improved to 20/70, the visual field defect vanished, and the VEP returned to almost normal values during a 1 year follow-up period. An objective causality assessment revealed that the adverse reaction was possibly related to ibuprofen.


CONCLUSIONS
Ocular toxicity with blurred vision and centrocecal visual field defects have been rarely associated with long-term ibuprofen intake. We report a case of retrobulbar optic neuritis with quadrant visual field defect following short-term but regular ibuprofen intake. Although idiopathic optic neuritis cannot be completely ruled out, the absence of other risk factors and additional findings plus the improvement after discontinuation of the drug speak for isolated toxic optic neuritis of the right eye.


CONCLUSIONS
Drug toxicity is an important differential diagnosis in retrobulbar optic neuritis. Clinicians should be aware of the potential optic toxicity, even with short-term use of a drug, and perform a thorough medication history in every patient with visual disturbances without a clear cause.
Gamulescu
Maria-A
MA
Department of Ophthalmology, University of Regensburg, Germany. gamulescu@eye-regensburg.de
Schalke
Berthold
B
Schuierer
Gerhard
G
Gabel
Veit-P
VP
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D005074:Evoked Potentials, Visual / Q000502:physiology; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009902:Optic Neuritis / Q000139:chemically induced* / Q000188:drug therapy; D014792:Visual Acuity; D014794:Visual Fields / Q000187:drug effects*
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007052:Ibuprofen; D008775:Methylprednisolone